Covid-19 briefing
Powered by
Download GlobalData’s Covid-19 Executive Briefing report
- ECONOMIC IMPACT -
Latest update: 03 March
The global economy is forecasted to return to pre-crisis levels by the end of 2021 or early 2022.
The IMF projects the Indian economy to grow by 11.5% in 2021, following an estimated 10.3% contraction in 2020.
5.5%
The IMF projects global economic growth at 5.5% for 2021, which is an upward revision from the 5.2% rise estimated in October 2020.
6.1%
The unemployment rate among G7 nations increased marginally to 6.1% in December, as compared to 6% in November.
Impact of Covid-19 on equity indices
- SECTOR IMPACT: PHARMA -
Latest update: 09 March
Vaccine development
33.5%
The UK leads the top economies in the percentage of population receiving one dose of a Covid-19 vaccine with 33.5% of the population having received their first dose.
46.20%
Globally, with 46.20% of its citizens now vaccinated, Gibraltar has the largest percentage of its population to have received all required doses of the prescribed vaccine.
Drug development pipelines
Developers with Covid-19 therapies and vaccines will benefit in the short-term, as intense investor interest will drive up stock prices and provide these companies with cash and resources to further pipeline development.
In Q1 2020 Bio/Pharma companies with a Covid-19 drug in the pipeline saw a smaller decrease in market cap than companies without a Covid-19 drug in the pipeline.
Difficulties with clinical trial execution and potential drug shortages could negatively impact all developers; however, pipeline companies focused on non-infectious therapies areas will suffer from the ability to raise the additional funds they need to survive.
In Q1 2020, Small cap Bio/Pharma companies without a Covid-19 drug saw the largest decrease in market cap.
Key pharma market developments
Share this article
